Functional impairment in patients with myotonic dystrophy type 1 can be assessed by an ataxia rating scale (SARA)
- PMID: 28168524
- PMCID: PMC5374179
- DOI: 10.1007/s00415-017-8399-x
Functional impairment in patients with myotonic dystrophy type 1 can be assessed by an ataxia rating scale (SARA)
Abstract
Myotonic dystrophy type 1 (DM1) is not characterised by ataxia per se; however, DM1 and ataxia patients show similar disturbances in movement coordination often experiencing walking and balance difficulties, although caused by different underlying pathologies. This study aims to investigate the use of a scale previously described for the assessment and rating of ataxia (SARA) with the hypothesis that it could have utility in DM1 patients as a measure of disease severity and risk of falling. Data from 54 DM1 patients were pulled from the PHENO-DM1 natural history study for analysis. Mean SARA score in the DM1 population was 5.45 relative to the maximum score of eight. A flooring effect (score 0) was observed in mild cases within the sample. Inter-rater and test-retest reliability was high with intraclass coefficients (ICC) of 0.983 and 1.00, respectively. Internal consistency was acceptable as indicated by a Cronbach's alpha of 0.761. Component analysis revealed two principle components. SARA correlated with: (1) all measures of muscle function tested, including quantitative muscle testing of ankle dorsiflexion (r = -0.584*), the 6 min walk test (r = -0.739*), 10 m walk test (r = 0.741*), and the nine hole peg test (r = 0.602*) and (2) measures of disease severity/burden, such as MIRS (r = 0.718*), MDHI (r = 0.483*), and DM1-Activ (r = -0.749*) (*p < 0.001). The SARA score was predicted by an interaction between modal CTG repeat length and age at sampling (r = 0.678, p = 0.003). A score of eight or above predicted the use of a walking aid with a sensitivity of 100% and a specificity of 85.7%. We suggest that further research is warranted to ascertain whether SARA or components of SARA are useful outcome measures for clinical trials in DM1. As a tool, it can be used for gathering information about disease severity/burden and helping to identify patients in need of a walking aid, and can potentially be applied in both research and healthcare settings.
Keywords: Balance; DM1; Falls; Myotonic dystrophy.
Conflict of interest statement
Conflicts of interest
Giovanni Di Paolo: This project was part of Mr. Di Paolo MRes’ research project. Cecilia Jimenez Moreno: Mrs Jimenez Moreno PhD studentship is a combined funding from Consejo Nacional de Ciencia y Tecnologia (CONACYT), Mexico (ID 611819) and a university scholarship from the MRC centre for neuromuscular diseases and the Barbour Foundation, UK. Nikoletta Nikolenko: Dr. Nikolenko’s contract is part of the PHENO-DM1 study grant. Antonio Atalaia: No conflict of interests. Darren G. Monckton: Prof. Monckton has been supported by awards from the Muscular Dystrophy UK, the Myotonic Dystrophy Support Group, and the European Union. Professor Monckton has also been a paid scientific consultant of Biogen Idec and AMO Pharma. Michela Guglieri: No conflict of interests. Hanns Lochmüller: Prof. Lochmüller has been awarded with the National Institute of Health Research IHR and Wyck grant to perform the PHENO-DM1 study.
Ethical standards
The author declares that the research documented in the submitted manuscript has been carried out in accordance with high research and ethical standards.
Figures
Similar articles
-
Modified dynamic gait index and limits of stability in myotonic dystrophy type 1.Muscle Nerve. 2018 Nov;58(5):694-699. doi: 10.1002/mus.26331. Epub 2018 Sep 23. Muscle Nerve. 2018. PMID: 30160307
-
Diastolic heart dysfunction is correlated with CTG repeat length in myotonic dystrophy type 1.Neurol Sci. 2018 Nov;39(11):1935-1943. doi: 10.1007/s10072-018-3530-z. Epub 2018 Aug 9. Neurol Sci. 2018. PMID: 30094526
-
Muscle force, balance and falls in muscular impaired individuals with myotonic dystrophy type 1: a five-year prospective cohort study.Neuromuscul Disord. 2015 Feb;25(2):141-8. doi: 10.1016/j.nmd.2014.11.004. Epub 2014 Nov 13. Neuromuscul Disord. 2015. PMID: 25475393
-
DM1 Phenotype Variability and Triplet Repeat Instability: Challenges in the Development of New Therapies.Int J Mol Sci. 2020 Jan 10;21(2):457. doi: 10.3390/ijms21020457. Int J Mol Sci. 2020. PMID: 31936870 Free PMC article. Review.
-
Myotonic dystrophies.Chang Gung Med J. 2005 Aug;28(8):517-26. Chang Gung Med J. 2005. PMID: 16265841 Review.
Cited by
-
Validation of Motor Outcome Measures in Myotonic Dystrophy Type 2.Front Neurol. 2020 Apr 21;11:306. doi: 10.3389/fneur.2020.00306. eCollection 2020. Front Neurol. 2020. PMID: 32373059 Free PMC article.
-
Analysis of the functional capacity outcome measures for myotonic dystrophy.Ann Clin Transl Neurol. 2019 Aug;6(8):1487-1497. doi: 10.1002/acn3.50845. Epub 2019 Jul 22. Ann Clin Transl Neurol. 2019. PMID: 31402614 Free PMC article.
-
Paving the way for a better understanding of the pathophysiology of gait impairment in myotonic dystrophy: a pilot study focusing on muscle networks.J Neuroeng Rehabil. 2019 Sep 18;16(1):116. doi: 10.1186/s12984-019-0590-0. J Neuroeng Rehabil. 2019. PMID: 31533780 Free PMC article.
-
Analysis of human urinary extracellular vesicles reveals disordered renal metabolism in myotonic dystrophy type 1.Nat Commun. 2025 Mar 5;16(1):2158. doi: 10.1038/s41467-025-56479-5. Nat Commun. 2025. PMID: 40044661 Free PMC article.
References
-
- Chen H. Atlas of genetic diagnosis and counselling. Totowa: Humana Press; 2006. p. 1077.
-
- Bird TD (2015) Myotonic dystrophy type 1. In: Pagon RA, Adam MP, Ardinger HH, et al (eds) GeneReviews® [Internet]. Seattle (WA), University of Washington, Seattle, 1993–2017. https://www.ncbi.nlm.nih.gov/books/NBK1165/ - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials